Researchers have identified the origin of ovarian cancer that develops in the fallopian tube, which opens doors to ...

Tumours shrank or stopped growing in almost one in three women (31 per cent) with low-grade serous ovarian cancer, which does ...

Almost a third (31%) of women with low-grade serous ovarian cancer, which does not respond well to chemotherapy, saw their ...

Scientists say the Royal Marsden hospitals' drug trial could change practice globally for serous form of ovarian cancer which ...

A groundbreaking study has uncovered the origin of one of the most aggressive forms of ovarian cancer, called high-grade ...

The completion of a new drug application for the combination of avutometinib and defactinib in KRAS-mutant ovarian cancer is ...

The first-ever Low-Grade Serous Ovarian Cancer (LGSOC) Awareness Day is dedicated to raising awareness, providing resources, and advocating for more research into this rare and recurrent form of ...

Researchers say that in the course of developing a new model for ovarian cancer, they've developed additional evidence that serous uterine cancer possibly begins in the fallopian tubes, not the uterus ...

The FDA has granted VLS-1488 fast track designation in patients with platinum-resistant high-grade serous ovarian cancer.

Most uterine cancers have excellent five-year survival rates—up to 95% for localized cancer. Serous uterine cancer is an exception, with five-year survival rates of 35% to 50% for stage 1 or 2 ...